Categories
Change Password!
Reset Password!
Normoxic
hypercapnia, a partial rebreathing device is a promising treatment option as it
effectively relieves pain in migraine patients.
New research results
showed that migraine could be effectively managed using normoxic hypercapnia.
The study got published recently in the Journal, Cephalalgia. One of the
primary reason behind migraine attacks is the impaired brain oxygen delivery,
which can be overcome via normoxic hypercapnia, as the method increases the
oxygen delivery in the brain by cerebral vasculature vasodilation and
hypercapnia. A compact partial rebreathing device can induce stable normoxic
hypercapnia. This pilot study introduced to evaluate primary data regarding
efficacy and safety of the device.
Adults with
migraine-with-aura self-administered the sham device or partial rebreathing
device at the time of migraine attack for 20 minutes. Eleven patients
accompanied self-treatment of migraine (21 with sham and 20 with the partial
rebreathing device). The mean oxygen saturation and End Tidal CO2 noticed in
the partial rebreathing device group was increased up to 97% and 24%,
respectively. A significant difference in the incidence of attacks with pain
relief at two hours was noticed, as was user comfort. However, the primary
endpoint showed no significance. From the first to the second-time usage of the
partial rebreathing device demonstrated a considerably increased efficacy. Very
mild side effects were seen; however adverse events were not observed. These
findings presented normoxic hypercapnia as a promising alternative option to
manage the migraine problem.
Cephalalgia
Treatment of acute migraine by a partial rebreathing device: A randomized controlled pilot study.
Cecilia H Fuglsang et al.
Comments (0)